Joseph G. Pressey · FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma
Follow
Article1 min read·Published Feb 2021Older

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Feb 2021 · 1 min read

In brief

In brief

This study identifies FOXF1 as a critical downstream target of the PAX3-FOXO1 fusion oncogene in fusion-positive rhabdomyosarcoma. CRISPR-mediated FOXF1 inactivation suppresses tumor growth and induces myogenic differentiation, revealing FOXF1 as a potential therapeutic target for this aggressive pediatric soft tissue malignancy.

Written by the GCMD Library team from the article.

Joseph G. Pressey

The PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis. Identifying key downstream targets of PAX3-FOXO1 will provide new therapeutic opportunities for treatment of FP-RMS. Herein, we demonstrate that Forkhead Box F1 (FOXF1) transcription factor is uniquely expressed in FP-RMS and is required for FP-RMS tumorigenesis. The PAX3-FOXO1 directly binds to FOXF1 enhancers and induces FOXF1 gene expression. CRISPR/Cas9 mediated inactivation of either FOXF1 coding sequence or FOXF1 enhancers suppresses FP-RMS tumorigenesis even in the presence of PAX3-FOXO1 oncogene. Knockdown or genetic knockout of FOXF1 induces myogenic differentiation in PAX3-FOXO1-positive FP-RMS. Over-expression of FOXF1 decreases myogenic differentiation in primary human myoblasts. In FP-RMS tumor cells, FOXF1 protein binds chromatin near enhancers associated with FP-RMS gene signature. FOXF1 cooperates with PAX3-FOXO1 and E-box transcription factors MYOD1 and MYOG to regulate FP-RMS-specific gene expression. Altogether, FOXF1 functions downstream of PAX3-FOXO1 to promote FP-RMS tumorigenesis.

Statements in this article

  1. PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis.

    Established
  2. FOXF1 transcription factor is uniquely expressed in FP-RMS and is required for FP-RMS tumorigenesis.

    Research
  3. PAX3-FOXO1 directly binds to FOXF1 enhancers and induces FOXF1 gene expression.

    Research
  4. CRISPR/Cas9 mediated inactivation of either FOXF1 coding sequence or FOXF1 enhancers suppresses FP-RMS tumorigenesis even in the presence of PAX3-FOXO1 oncogene.

    Research
  5. Knockdown or genetic knockout of FOXF1 induces myogenic differentiation in PAX3-FOXO1-positive FP-RMS.

    Research
  6. Over-expression of FOXF1 decreases myogenic differentiation in primary human myoblasts.

    Research
  7. In FP-RMS tumor cells, FOXF1 protein binds chromatin near enhancers associated with FP-RMS gene signature.

    Research
  8. FOXF1 cooperates with PAX3-FOXO1 and E-box transcription factors MYOD1 and MYOG to regulate FP-RMS-specific gene expression.

    Research
  9. FOXF1 functions downstream of PAX3-FOXO1 to promote FP-RMS tumorigenesis.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.